Product Code: IRTNTR43955
Technavio has been monitoring the overactive bladder therapeutics market and it is poised to grow by $ 311.17 mn during 2020-2024 progressing at a CAGR of 2% during the forecast period. Our reports on overactive bladder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing number of drug approvals and strategic alliances. In addition, increasing number of drug approvals is anticipated to boost the growth of the market as well.
The overactive bladder therapeutics market analysis includes product segment and geographic landscapes
Technavio's ‘overactive bladder therapeutics market ’ is segmented as below:
By Product:
- Anticholinergics
- Beta-3 adrenergic agonists
- Other OAB therapeutics
By Geographic Landscape:
- North America
- Europe
- Asia
- ROW
This study identifies the advent of combination therapy as one of the prime reasons driving the overactive bladder therapeutics market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our overactive bladder therapeutics market covers the following areas:
- Overactive bladder therapeutics market sizing
- Overactive bladder therapeutics market forecast
- Overactive bladder therapeutics market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading overactive bladder therapeutics market vendors that include AbbVie Inc., Astellas Pharma Inc., Endo International Plc, Johnson & Johnson, Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.. Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Table of Contents
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Anticholinergics - Market size and forecast 2019-2024
- Beta-3 adrenergic agonists - Market size and forecast 2019-2024
- Other OAB therapeutics - Market size and forecast 2019-2024
- Market opportunity by Product
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume drivers - Demand led growth
- Volume drivers - External factors
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Astellas Pharma Inc.
- Endo International Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan NV
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Exhibit
- 1: Key Finding 1
- 2: Key Finding 2
- 3: Key Finding 3
- 4: Key Finding 5
- 5: Key Finding 6
- 6: Key Finding 7
- 7: Key Finding 8
- 8: Parent market
- 9: Market characteristics
- 10: Offerings of vendors included in the market definition
- 11: Market segments
- 12: Global - Market size and forecast 2019 - 2024 ($ million)
- 13: Global market: Year-over-year growth 2019 - 2024 (%)
- 14: Five forces analysis 2019 & 2024
- 15: Bargaining power of buyers
- 16: Bargaining power of suppliers
- 17: Threat of new entrants
- 18: Threat of substitutes
- 19: Threat of rivalry
- 20: Market condition - Five forces 2019
- 21: Product - Market share 2019-2024 (%)
- 22: Comparison by Product
- 23: Anticholinergics - Market size and forecast 2019-2024 ($ million)
- 24: Anticholinergics - Year-over-year growth 2019-2024 (%)
- 25: Beta-3 adrenergic agonists - Market size and forecast 2019-2024 ($ million)
- 26: Beta-3 adrenergic agonists - Year-over-year growth 2019-2024 (%)
- 27: Other OAB therapeutics - Market size and forecast 2019-2024 ($ million)
- 28: Other OAB therapeutics - Year-over-year growth 2019-2024 (%)
- 29: Market opportunity by Product
- 30: Customer landscape
- 31: Market share by geography 2019-2024 (%)
- 32: Geographic comparison
- 33: North America - Market size and forecast 2019-2024 ($ million)
- 34: North America - Year-over-year growth 2019-2024 (%)
- 35: Europe - Market size and forecast 2019-2024 ($ million)
- 36: Europe - Year-over-year growth 2019-2024 (%)
- 37: Asia - Market size and forecast 2019-2024 ($ million)
- 38: Asia - Year-over-year growth 2019-2024 (%)
- 39: ROW - Market size and forecast 2019-2024 ($ million)
- 40: ROW - Year-over-year growth 2019-2024 (%)
- 41: Key leading countries
- 42: Market opportunity by geography ($ million)
- 43: Impact of drivers and challenges
- 44: Vendor landscape
- 45: Landscape disruption
- 46: Industry risks
- 47: Vendors covered
- 48: Market positioning of vendors
- 49: AbbVie Inc. - Overview
- 50: AbbVie Inc. - Business segments
- 51: AbbVie Inc. - Key offerings
- 52: AbbVie Inc. - Key customers
- 53: AbbVie Inc. - Segment focus
- 54: Astellas Pharma Inc. - Overview
- 55: Astellas Pharma Inc. - Business segments
- 56: Astellas Pharma Inc. - Key offerings
- 57: Astellas Pharma Inc. - Key customers
- 58: Astellas Pharma Inc. - Segment focus
- 59: Endo International Plc - Overview
- 60: Endo International Plc - Business segments
- 61: Endo International Plc - Key offerings
- 62: Endo International Plc - Key customers
- 63: Endo International Plc - Segment focus
- 64: Johnson & Johnson - Overview
- 65: Johnson & Johnson - Business segments
- 66: Johnson & Johnson - Key offerings
- 67: Johnson & Johnson - Key customers
- 68: Johnson & Johnson - Segment focus
- 69: Merck & Co. Inc. - Overview
- 70: Merck & Co. Inc. - Business segments
- 71: Merck & Co. Inc. - Key offerings
- 72: Merck & Co. Inc. - Key customers
- 73: Merck & Co. Inc. - Segment focus
- 74: Mylan NV - Overview
- 75: Mylan NV - Business segments
- 76: Mylan NV - Key offerings
- 77: Mylan NV - Key customers
- 78: Mylan NV - Segment focus
- 79: Ono Pharmaceutical Co. Ltd. - Overview
- 80: Ono Pharmaceutical Co. Ltd. - Business segments
- 81: Ono Pharmaceutical Co. Ltd. - Key offerings
- 82: Ono Pharmaceutical Co. Ltd. - Key customers
- 83: Ono Pharmaceutical Co. Ltd. - Segment focus
- 84: Pfizer Inc. - Overview
- 85: Pfizer Inc. - Business segments
- 86: Pfizer Inc. - Key offerings
- 87: Pfizer Inc. - Key customers
- 88: Pfizer Inc. - Segment focus
- 89: Sanofi - Overview
- 90: Sanofi - Business segments
- 91: Sanofi - Key offerings
- 92: Sanofi - Key customers
- 93: Sanofi - Segment focus
- 94: Teva Pharmaceutical Industries Ltd. - Overview
- 95: Teva Pharmaceutical Industries Ltd. - Business segments
- 96: Teva Pharmaceutical Industries Ltd. - Key offerings
- 97: Teva Pharmaceutical Industries Ltd. - Key customers
- 98: Teva Pharmaceutical Industries Ltd. - Segment focus
- 99: Currency conversion rates for US$
- 100: Research Methodology
- 101: Validation techniques employed for market sizing
- 102: Information sources
- 103: List of abbreviations
